Physician profile
Ting-Chi Lu
NPI 1649378787
$3,892.77
in general payments reported to CMS, 2019-2025
25 companies · $1,010 in 2025
The $1,010 reported for 2025 was more than what 78% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $615 · 2020: $113 · 2021: $136 · 2022: $433 · 2023: $1,026 · 2024: $561 · 2025: $1,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,571 · Education: $24.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,571.31 |
| Education | $24.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $704.94 | 2021-2025 | |
| Vifor Pharma, INC. | $564.40 | 2019-2024 | Veltassa, Korsuva |
| Travere Therapeutics, INC. | $325.37 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $266.57 | 2019-2025 | Lokelma, Farxiga |
| Aurinia Pharma U.S., INC. | $225.80 | 2023-2025 | Lupkynis |
| Mallinckrodt Enterprises LLC | $209.54 | 2019 | |
| Amgen INC. | $201.72 | 2019-2025 | Tavneos |
| Calliditas Therapeutics US INC. | $199.81 | 2023-2024 | Tarpeyo |
| Glaxosmithkline, LLC. | $182.42 | 2022-2025 | Benlysta, Jesduvroq |
| Otsuka America Pharmaceutical, INC. | $174.59 | 2019-2025 | Jynarque |
| Alexion Pharmaceuticals, INC. | $120.69 | 2022-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $112.46 | 2024-2025 | |
| Fresenius USA Marketing, INC. | $107.56 | 2019-2025 | Velphoro |
| Novo Nordisk INC | $88.40 | 2024-2025 | Ozempic |
| Veloxis Pharmaceuticals, INC. | $71.34 | 2025 | Envarsus |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $70.17 | 2019 | |
| Mallinckrodt Hospital Products INC. | $47.13 | 2020-2024 | Terlivaz |
| Ani Pharmaceuticals, INC. | $39.02 | 2023 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $38.01 | 2023 | Krystexxa |
| Opko Pharmaceuticals, LLC | $34.67 | 2019-2020 | |
| Apellis Pharmaceuticals, INC. | $27.04 | 2025 | |
| Daiichi Sankyo INC. | $24.74 | 2020 | |
| Lilly USA, LLC | $21.76 | 2024 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.35 | 2024 | Jardiance |
| Scpharmaceuticals INC. | $14.27 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ting-Chi Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.